Lucira Health, Inc.
LHDXDelisted Apr 12, 2023- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001652724
Lucira Health, Inc. was delisted on Apr 12, 2023; its insiders filed their last Form 4 on Mar 13, 2023; 29 institutions reported holding it in 13F filings for Q4 2022, worth $1.04M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:51 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2021! |
|---|---|
| Period end | Dec 31, 2021 |
| Filing | 10-K |
| Reported | Jan 10, 2022 |
| Revenue | $93.1M |
| Cost of revenue | $81.4M |
| Gross profit | $10.2M |
| Operating expenses | $75.4M |
| Research and development | $39.8M |
| Selling, general and administrative | $35.5M |
| Operating income | -$65.1M |
| Interest expense | $3.00K |
| Income tax | $17.0K |
| Net income | -$64.8M |
| Margins and growth | |
| Gross margin | 11.0% |
| Operating margin | -70.0% |
| Net margin | -69.7% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2021 |
|---|---|
| Period end | Dec 31, 2021 |
| Filing | 10-K |
| Reported | Jan 10, 2022 |
| Cash and equivalents | $106.0M |
| Accounts receivable | $27.2M |
| Inventory | $50.8M |
| Total current assets | $206.3M |
| Property, plant and equipment | $31.0M |
| Total assets | $240.4M |
| Accounts payable | $19.4M |
| Total current liabilities | $50.3M |
| Total liabilities | $51.6M |
| Shareholders' equity | $188.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2021 |
|---|---|
| Period end | Dec 31, 2021 |
| Filing | 10-K |
| Reported | Jan 10, 2022 |
| Operating cash flow | -$100.9M |
| Capital expenditures | $15.4M |
| Free cash flow | -$116.3M |
| Depreciation and amortization | $3.67M |
| Stock-based compensation | $8.11M |
| Investing cash flow | -$15.4M |
| Financing cash flow | $161.7M |
| Net change in cash | $45.4M |
| Ratio | |
| Stock-based compensation, % of revenue | 8.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.